ArticleThe Permanente journal2025
Long-Term Survivor of Laryngeal Small Cell Neuroendocrine Carcinoma.
Article in The Permanente journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell neuroendocrine carcinoma (SCNC) of the larynx is an exceptionally rare subset of laryngeal carcinoma with a clinically aggressive course and poor prognosis. Long-term survival is rare, and treatment strategies remain nonstandardized due to limited data. In this report, the authors present a case of a 51-year-old male who presented with stage IVa laryngeal SCNC and no distant metastasis, treated with a combination of platinum-based chemotherapy and radiation, who has survived for more than 5 years. This case represented 1 of few reported instances of extended disease-free survival in laryngeal SCNC, highlighting the potential benefit of aggressive multimodal treatment, even in advanced-stage disease. In addition to diagnosis and management, this case may prompt further discussion about the role of surgery in select patients and the need for individualized, patient-centered survivorship care for management of posttreatment sequalae. Although limited to a single case, these findings underscore the need for further research into effective treatment and surveillance strategies for this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.